High-risk early breast cancer in patients under 40 years of age:  Improved clinical outcome with total estrogen blockade and tailored chemotherapy

Recchia,Francesco; Candeloro,Giampiero; Discepoli,Stefania; Grimaldi,Marisa; Desideri,Giovambattista; Necozione,Stefano; Rea,Silvio

doi:10.3892/etm.2010.135

High-risk early breast cancer in patients under 40 years of age: Improved clinical outcome with total estrogen blockade and tailored chemotherapy

Authors:
- Francesco Recchia
- Giampiero Candeloro
- Stefania Discepoli
- Marisa Grimaldi
- Giovambattista Desideri
- Stefano Necozione
- Silvio Rea
View Affiliations

Affiliations: Unità Operativa di Oncologia, Ospedale Civile di Avezzano, AQ, Italy, Unità Operativa di Anatomia Patologica, Ospedale Civile di Avezzano, AQ, Italy, Geriatria, Università degli Studi dell'Aquila, AQ, Italy, Epidemiologia Clinica, Università degli Studi dell'Aquila, AQ, Italy, Fondazione ‘Carlo Ferri’, Monterotondo, Rome, Italy
Published online on: July 21, 2010 https://doi.org/10.3892/etm.2010.135
Pages: 867-872

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This multicenter prospective trial assessed the outcome in 63 patients, 40 years of age or younger, with high-risk early breast cancer (HREBC), included in an ovarian protection study. The patients were treated with a luteinizing hormone-releasing hormone (LH-RH) analogue administered for 5 years, tailored chemotherapy and an aromatase inhibitor, in estrogen receptor-positive (ER+) patients. T-regulatory cells (T-regs) and vascular endothelial growth factor (VEGF) were measured at baseline and yearly. The mean age of the patients was 36 years (range 26-40). Sixty-five percent had ER+ tumors, 24% had negative axillary nodes with tumors >1 cm and high histological grade with lymphovascular invasion, while 76% had a mean of 3.6 positive axillary nodes (range 1-21). Serum estradiol was maintained at values <40 pg/ml in all of the patients. A statistically significant decrease in VEGF (P<0.0001) and T-regs (P<0.0001), with respect to baseline values, was observed after LH-RH administration. After a median follow-up of 110 months, the 10-year progression-free and overall survival rates were 86.1 and 89.7%, respectively. These data revealed that the administration of an LH-RH analogue to HREBC patients, followed by chemotherapy and hormonal therapy, decreased VEGF and T-regs and improved the expected clinical outcome.

View Figures

View References

1.	Varga D, Koenig J, Kuhr K, et al: Comparison of early onset breast cancer patients to older premenopausal breast cancer patients. Arch Gynecol Obstet. Jan;2010.(E-pub ahead of print).
2.	El Saghir NS, Seoud M, Khalil MK, et al: Effects of young age at presentation on survival in breast cancer. BMC Cancer. 6:1942006.PubMed/NCBI
3.	Anders CK, Hsu DS, Broadwater G, et al: Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 26:3324–3330. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Bollet MA, Sigal-Zafrani B, Mazeau V, et al: Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first. Radiother Oncol. 82:272–280. 2007.PubMed/NCBI
5.	Wendy Y and Chen MD: MPH. Exogenous and endogenous hormones and breast cancer. Best Pract Res Clin Endocrinol Metab. 22:573–585. 2008. View Article : Google Scholar : PubMed/NCBI
6.	Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J and Perrot-Applanat M: Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res. 62:4977–4984. 2002.
7.	Tai P, Wang J, Jin H, et al: Induction of regulatory T cells by physiological level estrogen. J Cell Physiol. 214:456–464. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Linderholm BK, Gruvberger-Saal S, Fernö M, Bendahl PO and Malmström P: Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer. Breast. 7:484–491. 2008. View Article : Google Scholar
9.	Xu L, Xu W, Qiu S and Xiong S: Enrichment of CCR6(+) Foxp3(+) regulatory T cells in the tumor mass correlates with impaired CD8(+) T cell function and poor prognosis of breast cancer. Clin Immunol. 135:466–475. 2010.
10.	Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 365:1687–1717. 2005.PubMed/NCBI
11.	Parulekar WR, Day AG, Ottaway JA, et al: National Cancer Institute of Canada Clinical Trials Group. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study – NCIC CTG MA5. J Clin Oncol. 23:6002–6008. 2005.PubMed/NCBI
12.	Goel S, Sharma R, Hamilton A and Beith J: LH-RH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev. 4:CD0045622009.
13.	LH-RH-agonists in Early Breast Cancer Overview Group; Cuzick J, Ambroisine L, Davidson N, et al: Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 369:1711–1723. 2007. View Article : Google Scholar
14.	Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 365:60–62. 2005.
15.	Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 350:1081–1092. 2004.PubMed/NCBI
16.	Thürlimann B, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 353:2747–2757. 2005.PubMed/NCBI
17.	Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J Natl Cancer Inst. 97:1262–1271. 2005. View Article : Google Scholar
18.	Rossi E, Morabito A, Di Rella F, et al: Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. Clin Oncol. 27:3192–3197. 2009. View Article : Google Scholar
19.	Recchia F, Sica G, De Filippis S, Rosselli M and Rea S: Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer. A phase II pilot study. Anticancer Drugs. 13:417–424. 2002. View Article : Google Scholar : PubMed/NCBI
20.	Recchia F, Saggio G, Amiconi G, et al: Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer. 106:514–523. 2006. View Article : Google Scholar
21.	Recchia F, Saggio G, Cesta A, et al: Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy. Anticancer Res. 25:3149–3157. 2005.PubMed/NCBI
22.	Recchia F, Accorsi P, Bonfini T, et al: Randomized trial of sequential administration of G-CSF and GM-CSF vs. G-CSF alone following peripheral blood progenitor cell autograft in solid tumors. J Interferon Cytokine Res. 20:171–177. 2000. View Article : Google Scholar
23.	Recchia F, De Fillipis S, Piccinini M and Rea S: High-dose carboplatin, cyclophosphamide, etoposide with hematological growth factors, without stem cell support in patients with advanced cancer. Anticancer Res. 23:4141–4147. 2003.PubMed/NCBI
24.	Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 10:1–10. 1989. View Article : Google Scholar : PubMed/NCBI
25.	Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:457–481. 1958. View Article : Google Scholar
26.	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
27.	Verheul HM, Hoekman K, Luykx-de Bakker S, et al: Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res. 3:2187–2190. 1997.PubMed/NCBI
28.	Bines J, Oleske DM and Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 5:1718–1729. 1996.PubMed/NCBI
29.	Fraser HM and Duncan WC: SRB Reproduction, Fertility and Development Award Lecture 2008. Regulation and manipulation of angiogenesis in the ovary and endometrium. Reprod Fertil Dev. 21:377–392. 2009. View Article : Google Scholar : PubMed/NCBI
30.	Krüssel J, Behr B, Hirchenhain J, et al: Expression of vascular endothelial growth factor mRNA in human preimplantation embryos derived from tripronuclear zygotes. Fertil Steril. 74:1220–1226. 2000.PubMed/NCBI
31.	Applanat MP, Buteau-Lozano H, Herve MA and Corpet A: Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression. Adv Exp Med Biol. 617:437–444. 2008. View Article : Google Scholar : PubMed/NCBI
32.	Dabrosin C: Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo. Clin Cancer Res. 11:8036–8041. 2005. View Article : Google Scholar
33.	Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J and Perrot-Applanat M: Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res. 62:4977–4984. 2002.
34.	Gasparini G: Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 5(Suppl 1): 37–44. 2000. View Article : Google Scholar
35.	Prieto GA and Rosenstein Y: Oestradiol potentiates the suppressive function of human CD4 CD25 regulatory T cells by promoting their proliferation. Immunology. 118:58–65. 2006. View Article : Google Scholar : PubMed/NCBI
36.	Tai P, Wang J, Jin H, et al: Induction of regulatory T cells by physiological level estrogen. J Cell Physiol. 214:456–464. 2008. View Article : Google Scholar : PubMed/NCBI
37.	Arruvito L, Sanz M, Banham AH and Fainboim L: Expansion of CD4⁺CD25⁺ and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. J Immunol. 178:2572–2578. 2007.PubMed/NCBI
38.	Gobert M, Treilleux I, Bendriss-Vermare N, et al: Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 69:2000–2009. 2009. View Article : Google Scholar
39.	Davidson NE, O'Neill AM, Vukov AM, et al: Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 23:5973–5882. 2005. View Article : Google Scholar